What happened to Senores pharmaceuticals IPO?

Updated - December 24, 2024 at 08:55 AM. The Ahmedabad -based Senores Pharmaceuticals, which launched its ₹582.11 crore IPO on Friday at a price band of ₹372-391, has received a robust response from all investors. The IPO, which closes today, saw a subscription of 13,93 times.

Why should investors subscribe to Xiaota pharmaceuticals?

Analysts advised investors to subscribe to the issue as the valuations are attractive and the demand for pharmaceuticals remains high. At the upper price band, the company is valued at P/E of 55x with a market cap of Rs 1801 crore post issue of equity shares and return on net worth of 23.6% based on FY24.

Will a pipeline of drug candidates propel the stock higher in 2025?

Updates from an extensive pipeline of drug candidates could propel the stock higher in 2025. Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.